SU1685454A1 - Burn treatment agent "xymedon" - Google Patents
Burn treatment agent "xymedon" Download PDFInfo
- Publication number
- SU1685454A1 SU1685454A1 SU772452993A SU2452993A SU1685454A1 SU 1685454 A1 SU1685454 A1 SU 1685454A1 SU 772452993 A SU772452993 A SU 772452993A SU 2452993 A SU2452993 A SU 2452993A SU 1685454 A1 SU1685454 A1 SU 1685454A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- xymedon
- dimethyldihydropyrimidone
- burn
- treatment agent
- agent
- Prior art date
Links
Description
мm
ёyo
Изобретение относитс к медицине противоожоговых средств.This invention relates to anti-burn medicine.
Цель изобретени - повышение фармакологической активности.The purpose of the invention is to increase the pharmacological activity.
В качестве лекарственного средства примен ют N-( /9-оксиэтилу-4,6-диметилди- гидропиримидон-2 (Ксимедон), обладающий высокой регенеративной активностью, известный как химическое соединение.N- ((9-hydroxyethyl-4,6-dimethyldihydropyrimidone-2 (Xymedon)) with a high regenerative activity, known as a chemical compound, is used as a drug.
Ксимедон - N- /3-оксиэтил)-4,6-диме- тилдигидропиримидон-2 - получен взаимодействием гидрохлорида 2-ок- си-4,6-диметилпиримидина с этилен- хлоргидрином в присутствии 2 моль NaOH в среде н-бутанола.Xymedon - N- / 3-hydroxyethyl) -4,6-dimethyldihydropyrimidone-2 - is obtained by reacting 2-ox-4,6-dimethylpyrimidine hydrochloride with ethylene chlorohydrin in the presence of 2 mol of NaOH in n-butanol medium.
Препарат представл ет собой кристаллический порошок от белого до светло-розового цвета с т.пл 137 , 5-139,5°С Хорошо растворим в воде.The preparation is a white to light pink crystalline powder with mp 137, 5-139.5 ° C. It is soluble in water.
П р и м е р. В опыт берутс морские свинки самцы и самки массой 300-380 г, за день до нанесени ожога необходима поверхность депиллируетс 10%-ным раствором сернистого натри , нанос тс по 2 стандартных ожога на боковые поверхности туловища. На следующий день после ожога в зависимости от принадлежности к группам (опытна , контрольна группа, леченна метилурацилом) начинаетс введение ксимедона в дозе 750 мг/кг, метилурацила - в дозе 100 мг/кг и физиологического раствора по 0.5 мл на 100 г массы ежедневно 1 раз в сутки. Сроки наблюдени вз ты в динамике: 37, 15, 20, 25 и 30 сут. В опытной группе на 25-й день у всех исследуемых животных практически наступает выздоровление , в группе, леченной метилурацилом,PRI me R. Guinea pigs, males and females weighing 300–380 g, are taken into the experiment, the day before the burn is applied, the surface is depillated with a 10% solution of sodium sulphide, 2 standard burns are applied to the lateral surfaces of the body. The day after the burn, depending on the group membership (experimental, control group, treated with methyluracil), xymedon is administered at a dose of 750 mg / kg, methyluracil at a dose of 100 mg / kg and saline at 0.5 ml per 100 g of weight daily 1 once a day. The time of observation is taken in the dynamics: 37, 15, 20, 25 and 30 days. In the experimental group on the 25th day, all the studied animals almost recovered, in the group treated with methyluracil,
О 00 СЯO 00 SJ
ЈьЈ
слcl
JVJv
подобна картин.) заживлени отмечена лишь к 30-му дню.similar to the pictures.) of healing is noted only by the 30th day.
Морские свинки забивались путем дека- питации, при забое забирали кровь дл проведени исследовани р да биохимических показателей.Guinea pigs were slaughtered by decapitalization, blood was collected at slaughter for a series of biochemical indicators.
Использование ксимедона показало, что он вл етс эффективным средством лечени ожогов в силу своей высокой лротмвовоспалительной и регенеративной 10 и хронических лейкемических формах лей- активности. Лечебный эффект выражаетс в коза, лимфогрануломотоза, злокачествен- быстрейшем заживлении раневой поверхности , отпадении струпа на более ранних сроках, в улучшении морфологической и чи- стохимической картины поврежденной ко- 15 жи и восстановлении биохимических показателей, указывающих на нормализацию метаболических процессов.The use of xymedon has shown that it is an effective treatment for burns due to its high lung inflammatory and regenerative 10 and chronic leukemic forms of leukemia. The therapeutic effect is expressed in goat, lymphogranulomatosis, malignancy, faster healing of the wound surface, elimination of the scab in earlier periods, improvement of the morphological and computational picture of the damaged skin and restoration of biochemical indicators indicating normalization of metabolic processes.
ных заболевани х костного мозга.diseases of the bone marrow.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU772452993A SU1685454A1 (en) | 1977-02-14 | 1977-02-14 | Burn treatment agent "xymedon" |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU772452993A SU1685454A1 (en) | 1977-02-14 | 1977-02-14 | Burn treatment agent "xymedon" |
Publications (1)
Publication Number | Publication Date |
---|---|
SU1685454A1 true SU1685454A1 (en) | 1991-10-23 |
Family
ID=20695736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU772452993A SU1685454A1 (en) | 1977-02-14 | 1977-02-14 | Burn treatment agent "xymedon" |
Country Status (1)
Country | Link |
---|---|
SU (1) | SU1685454A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4323615A1 (en) * | 1993-07-12 | 1995-01-19 | Schreiner Edelgard | Compositions to prevent premature ageing of the skin |
WO2008002196A1 (en) | 2006-06-19 | 2008-01-03 | Lev Davidovich Rasnetsov | Pharmaceutical composition for treating burns (variants) and a method for the production thereof (variants) |
-
1977
- 1977-02-14 SU SU772452993A patent/SU1685454A1/en active
Non-Patent Citations (1)
Title |
---|
Резник B.C., Пашкуров Н.Г. Взаимодействие окси- и меркаптопиримидинов с этилен- и пропиленхлоргидринами. - Извести АН СССР, сер. Хими , 1966, № 91Б13. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4323615A1 (en) * | 1993-07-12 | 1995-01-19 | Schreiner Edelgard | Compositions to prevent premature ageing of the skin |
WO2008002196A1 (en) | 2006-06-19 | 2008-01-03 | Lev Davidovich Rasnetsov | Pharmaceutical composition for treating burns (variants) and a method for the production thereof (variants) |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4708965A (en) | Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives | |
PT82361B (en) | Process for the preparation of benzo-naphthalene derivatives and their use in the pharmaceutical and cosmetic fields | |
DE701443T1 (en) | Terfanadine metabolites and their optically pure isomers for the treatment of allegic diseases | |
IT1252868B (en) | ANTI-PHALALGIC PHARMACEUTICAL COMPOSITION FOR ENDONASAL ADMINISTRATION, PROCEDURE TO PREPARE IT AND ITS THERAPEUTIC USE | |
DK330685D0 (en) | COMBINATION PREPARATION AND ITS USE | |
JPS6470415A (en) | Skin permeable remedy system | |
DE4394931T1 (en) | Use of norastemizole for the treatment of allergic diseases | |
FI854926A0 (en) | FREEZING FOR PHARMACOLOGICAL ACTIVE PYRROLOBENSIMIDAZOLER. | |
ES472847A1 (en) | 2-Bromo-ergosine and its acid addition salts, method for its preparation and its application as a medicine. | |
SU1685454A1 (en) | Burn treatment agent "xymedon" | |
WO1991002529A2 (en) | Product and method for killing abnormal vertebrate cells | |
KR920004387A (en) | 4-substituted dihydropyrido [4,3-d] pyrimidines as topical anti-inflammatory agents for the treatment of analgesics and skin diseases | |
KR920700627A (en) | Novel use of 1-phenyl-2-aminoethanol derivatives as therapeutic agents | |
KR890006621A (en) | Anti-anxiety | |
ES354055A1 (en) | Anilides of quinuclidine-2- and quinuclidine-3-carboxylic acid | |
NO173137C (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE COMPOUNDS | |
JPS5545681A (en) | 88chloroo66hydroxyy55methylbenzoic acid derivative | |
Fox et al. | Virulence of Pseudomonas infection in burned rats and mice: comparative efficacy of silver sulfadiazine and mafenide | |
PT653939E (en) | USE OF A HYMENOPTERE POISON FOR THE MANUFACTURE OF A DRUG FOR THE TREATMENT OF DNA VIRUS INFECTIONS | |
RU2668966C1 (en) | Complex salts of acidum acexamicum, stimulating regeneration of bone tissue, accelerating processes of reparative osteogenesis, stimulating mineralization of bone tissue in osteoporosis | |
US3026247A (en) | Pharmaceutical preparation | |
ES477630A1 (en) | Salts of dithiodialkanesulfonic acids for use in cytostatic therapy with alkylating agents. | |
SE8203856D0 (en) | NOVEL DERIVATIVES OF GUANINE II | |
DE3275060D1 (en) | Use of beta-(1-adamantyl)-alpha, alpha-dimethylethylamine for the manufacture of a medicament for the treatment of otitis externa in dogs | |
Frank et al. | PANCYTOPENIA FROM MESANTOIN: Report of Two Cases |